导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.69% | 1183/4773 |
| 近一周 | -2.51% | 2409/5462 |
| 近一月 | -4.94% | 2882/5421 |
| 近一季 | -7.36% | 2374/5209 |
| 近半年 | -3.88% | 2348/4920 |
| 近一年 | 11.37% | 921/4366 |
| 近两年 | 73.43% | 905/2954 |
| 近三年 | 37.34% | 788/2253 |
| 成立以来 | 69.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.00% 1103/4961 |
20.43% 1228/5312 |
- - |
- - |
| 2025 | 34.97% 1012/4813 |
3.58% 1067/3635 |
2.97% 1229/4076 |
23.39% 1545/4524 |
2.55% 913/4813 |
| 2024 | 2.85% 1953/3463 |
-2.04% 1311/2808 |
-3.71% 1411/3014 |
10.04% 2653/3129 |
-0.91% 1542/3463 |
| 2023 | -9.05% 1093/2656 |
6.17% 716/2280 |
-5.46% 1464/2385 |
-4.30% 1108/2515 |
-5.32% 1321/2655 |
| 2022 | -16.06% 447/2207 |
-10.09% 377/1919 |
5.42% 906/2016 |
-10.78% 450/2113 |
-0.73% 1643/2208 |
| 2021 | 16.66% 263/1822 |
3.21% 193/1255 |
7.87% 663/1330 |
4.58% 335/1466 |
0.20% 1160/1822 |
| 2020 | - - |
- - |
18.72% 327/1067 |
8.99% 686/1164 |
2.04% 1012/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 嘉实中证500指数增强C VS. 长安沪深300非周期A(740101) |